Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02560025 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT02560025: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02560025 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02560025, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This research study is studying a targeted therapy (a form of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells) as a possible treatment for high-risk acute myeloid leukemia. The names of the study interventions involved in this study are: * Alisertib / MLN8237 * Cytarabine / Cytosine Arabinoside * Idarubicin / Idarubicin hydrochloride * Daunorubicin (Can be used in place of idarubicin)
Interventions
- DRUG Cytarabine
- DRUG Idarubicin
- DRUG Daunorubicin
- DRUG Alisertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02560025
The ClinicalTrials.gov registry entry for NCT02560025 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cytarabine is the first listed.
NCT02560025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02560025 about?
NCT02560025 is a clinical study titled "Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML". This research study is studying a targeted therapy (a form of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells) as a possible treatment for high-risk acute myeloid leukemia. The names of the study interventions involv...
What is the current status of trial NCT02560025?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2015-12. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02560025?
The interventions under investigation include: Cytarabine (DRUG), Idarubicin (DRUG), Daunorubicin (DRUG), Alisertib (DRUG).
Who is sponsoring clinical trial NCT02560025?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.